Nuvectis Pharma (NASDAQ:NVCT) Posts Earnings Results

Nuvectis Pharma (NASDAQ:NVCT) announced its quarterly earnings results on Tuesday. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01, RTT News reports. During the same quarter last year, the firm earned ($0.37) EPS.

Nuvectis Pharma Price Performance

Shares of NASDAQ NVCT traded up $0.47 during midday trading on Wednesday, hitting $7.90. The company’s stock had a trading volume of 133,645 shares, compared to its average volume of 102,662. Nuvectis Pharma has a 1 year low of $5.85 and a 1 year high of $12.10. The business’s fifty day simple moving average is $6.79 and its two-hundred day simple moving average is $6.67. The firm has a market capitalization of $147.34 million, a price-to-earnings ratio of -5.86 and a beta of 0.41.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.